BioNTech, the German biotech group behind the first approved Covid-19 vaccine, warned there was “no data” to support moves to delay the second dose of the jab with the aim of reaching as many people as possible with limited supplies.
研發(fā)了首款獲批新型冠狀病毒肺炎（COVID-19，即2019冠狀病毒病）疫苗的德國生物科技企業(yè)BioNTech警告稱，為了在疫苗供應(yīng)有限的情況下盡可能覆蓋更多人而延遲第二針接種的舉動，是“沒有數(shù)據(jù)”支持的。
您已閱讀5%（336字），剩余95%（6307字）包含更多重要信息，訂閱以繼續(xù)探索完整內(nèi)容，并享受更多專屬服務(wù)。